Ochre Bio develops a deep phenotyping platform that utilizes human models to generate genomic and phenotypic data at scale, enabling the rapid development of RNA therapies for chronic liver disease. This approach addresses the rising prevalence of liver disease, which is a leading cause of premature death globally, by providing targeted treatments for patients with late-stage conditions.
Funding
$39.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+6Founders
Product
Problem
Chronic liver diseases are a leading cause of premature death globally, with limited treatment options available for patients with late-stage conditions beyond liver transplantation. A significant unmet need exists for targeted therapies that can address the rising prevalence of these diseases, including MASH (metabolic dysfunction-associated steatohepatitis).
Solution
Ochre Bio is developing RNA therapies for chronic liver diseases by employing a deep phenotyping platform that utilizes human liver models to generate genomic and phenotypic data at scale. This approach aims to causally map genes to cells, histology, and clinical data, enabling the identification of novel drug targets and the development of more effective treatments. Ochre Bio's platform integrates human discovery, human validation, and RNA therapy development to accelerate the progression of targets to validated leads using human data. The human validation platform includes advanced human systems such as human cell co-culture, diseased liver tissue culture, and the perfusion of whole human livers.
Target Audience
The primary target audience includes patients with chronic liver diseases, particularly those with late-stage conditions, as well as pharmaceutical companies and research institutions focused on developing novel liver disease therapies.
Features
- Deep phenotyping of human liver samples and models to map genes to cells and clinical data.
- Human validation platform utilizing human cell co-culture, diseased liver tissue culture, and whole human liver perfusion.
- RNA chemistry platform for developing therapies with a higher chance of clinical success.
- Target validation using human data in weeks, rather than years.
- Capabilities in cellular senescence, macroautophagy, beta oxidation, de novo lipogenesis, ER stress, intrinsic apoptosis, and glucose metabolism.